We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Comparison of the Effects of Nebivolol and Bisoprolol on Systemic Vascular Resistance in Patients with Essential Hypertension: β-Blockade and Haemodynamics in Hypertension.
- Authors
Brett, S.; Forte, P.; Chowienczyk, P.; Benjamin, N.; Ritter, J.
- Abstract
Objective: To compare the haemodynamic effects of nebivolol, a highly selective antagonist of β-adrenergic receptors with additional actions caused via the L-arginine/nitric oxide pathway, with those of bisoprolol, another selective β-adrenergic receptor antagonist. Patients and methods: The study had a double-blind, randomised, crossover design, and was performed in an outpatient setting. Study participants comprised 15 patients (11 men, four women, aged 29 to 69 years) with uncomplicated mild essential hypertension. Patients were randomised to receive nebivolol (5mg orally daily) or bisoprolol (10mg orally daily) for 2 weeks, followed by a 2-week washout and 2 weeks of the other treatment. Measurements (by mercury sphygmomanometer and bioimpedance) were made at the end of each baseline and each active treatment period. Results: Mean heart rate fell during active treatment (from 65 ± 2 to 53 ± 3 beats/min during bisoprolol, p < 0.05, and from 64 ± 3 to 59 ± 3 beats/min during nebivolol). Systolic/diastolic blood pressure fell during active treatments to a similar extent with each treatment (bisoprolol: 143 ± 3/90 ± 2mm Hg to 127 ± 3/80 ± 2mm Hg; nebivolol: 144 ± 4/92 ± 2mm Hg to 131 ± 4/83 ± 3mm Hg; each p < 0.01). In contrast, the systemic vascular resistance index fell during nebivolol (from 2854 ± 201 to 2646 ± 186 dyn•sec•cm5•m, p < 0.05), but did not change significantly during bisoprolol treatment (baseline 2848 ± 177, with treatment 2787 ± 159 dyn•sec•cm5•m). Conclusion: The fall in systemic vascular resistance index during nebivolol (but not bisoprolol) treatment can be explained on the basis of a systemic vasodilator action of nebivolol. The clinical importance of this action requires further investigation.
- Subjects
ANTIHYPERTENSIVE agents; BISOPROLOL; HYPERTENSION; THERAPEUTICS; ADRENERGIC receptors; DRUG efficacy; CHEMICAL inhibitors
- Publication
Clinical Drug Investigation, 2002, Vol 22, Issue 6, p355
- ISSN
1173-2563
- Publication type
Article
- DOI
10.2165/00044011-200222060-00002